Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Lannett Company, Inc. : Lannett Reports Record Fiscal 2013 Third Quarter Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2013 | 10:10pm CEST

--Net Sales Increase 27%; Net Income More than Doubles; Company Increases Guidance for Full Year--

Lannett Company, Inc. (NYSE MKT: LCI) today reported continued strong momentum, with sharply improved financial results for its fiscal 2013 third quarter ended March 31, 2013, compared with the prior year period.

For the fiscal 2013 third quarter, net sales rose significantly to $39.0 million, up 27% from $30.7 million for last year's third quarter. Gross profit increased to $15.2 million from $10.9 million for the fiscal 2012 third quarter. As a percentage of net sales, gross margin increased to 39% from 35% last year. Research and development (R&D) expenses were $5.2 million, compared with $2.9 million for the fiscal 2012 third quarter. Selling, general and administrative (SG&A) expenses decreased to $5.2 million, from $5.6 million in the same quarter of the prior year. Operating income nearly doubled to $4.7 million from $2.4 million for the third quarter of fiscal 2012. Net income attributable to Lannett Company rose to $3.9 million, or $0.14 per diluted share, from $1.7 million, or $0.06 per diluted share, for the same period last year.

"Our fiscal 2013 third quarter net sales and net income were the highest in the company's history," said Arthur Bedrosian, president and chief executive officer of Lannett. "Our performance reflected continued solid sales from our base products, combined with strong sales of recently approved products. Gross margin percentage increased due to favorable sales mix and price increases, as well as enhanced manufacturing efficiencies related to higher sales volume. With 15 product applications currently pending at the FDA and our ramped up investment in product development, we believe we are well-positioned for continued positive results."

For the first nine months of fiscal 2013, net sales increased to $110.9 million from $87.3 million for the corresponding prior year period. Gross profit rose to $42.2 million from $26.9 million last year. R&D expenses were $12.6 million, compared with $7.9 million for the first nine months of fiscal 2012. SG&A expenses amounted to $16.6 million, versus $14.8 million for the first nine months of fiscal 2012. Operating income more than tripled to $13.1 million from $4.3 million a year ago. Net income attributable to Lannett Company increased to $9.8 million, equal to $0.34 per diluted share, from $2.5 million, or $0.09 per diluted share, for the first nine months of fiscal 2012. Net income for the most recent year-to-date period included a favorable litigation settlement of $1.3 million, equal to $0.03 per diluted share.

Upward Revised Guidance for Fiscal 2013

Based on Lannett's current outlook, the company revised its financial guidance upward for the full 2013 fiscal year as follows:

  • Net sales of $147 million to $149 million, up from the previous guidance of $140 million to $142 million;
  • Gross margin as a percentage of net sales of approximately 38%, up from 36% to 37%;
  • R&D expense in the range of $16 million to $17 million, down from $17 million to $18 million;
  • SG&A expense ranging from $22 million to $23 million, versus $24 million to $25 million;
  • Other income of approximately $2.0 million, essentially equal to the litigation settlement the company reported in the first quarter, and year-to-date gains on investments;
  • The full year effective tax rate in the range of 35% to 37%; and
  • Capital expenditures in the range of $7 million to $9 million, versus $10 million to $12 million in the previous guidance.

Conference Call Information and Forward-Looking Statements

Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for the fiscal 2013 third quarter ended March 31, 2013. The conference call will be available to interested parties by dialing 877-261-8992 from the U.S. or Canada, or 847-619-6548 from international locations, passcode 34792521. The conference call will also be available through a live audio Internet broadcast at www.lannett.com. A playback of the call will be archived and accessible at this site for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company's financial status and performance and regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, achieving the financial metrics stated in the company's upward revised guidance, expected product approvals, the successful commercialization of products in development, product applications pending at the FDA and recently approved products, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company's Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.

LANNETT COMPANY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except share and per share data)
               
Three months ended Nine months ended
March 31, March 31,

2013

2012

2013

2012

 
Net sales $ 39,022 $ 30,688 $ 110,880 $ 87,300
Cost of sales 23,321 19,276 67,105 58,789
Amortization of intangible assets 471 471 1,412 1,409
Product royalties   60     50     146     168  
 
Gross profit 15,170 10,891 42,217 26,934
 
Research and development expenses 5,229 2,911 12,565 7,850
Selling, general, and administrative expenses   5,245     5,616     16,571     14,780  
 
Operating income   4,696     2,364     13,081     4,304  
 
Other income (expense):
Foreign currency gain (loss) - (3 ) 3 (6 )
Gain on sale of assets 93 - 51 4
Realized gain on investments 353 361 449 215
Unrealized gain (loss) on investments 185 105 394 (46 )
Litigation settlement - - 1,250 -
Interest and dividend income 22 28 84 117
Interest expense   (59 )   (64 )   (194 )   (214 )
  594     427     2,037     70  
 
Income before income tax expense 5,290 2,791 15,118 4,374
Income tax expense   1,327     1,057     5,353     1,788  
Net income 3,963 1,734 9,765 2,586
Less net income attributable to noncontrolling interest   (16 )   (16 )   (11 )   (53 )
 
Net income attributable to Lannett Company, Inc. $ 3,947   $ 1,718   $ 9,754   $ 2,533  
 
Earnings per common share - Lannett Company, Inc.:
Basic 0.14 0.06 0.34 0.09
Diluted 0.14 0.06 0.34 0.09
 
Weighted average number of shares outstanding:
Basic 28,490,175 28,571,062 28,371,189 28,509,595
Diluted 29,115,941 28,719,669 28,644,831 28,668,281
 

LANNETT COMPANY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
(In thousands, except share and per share data)
     

(Unaudited)

   

March 31, 2013

June 30, 2012
 

ASSETS

Current Assets
Cash and cash equivalents $ 33,066 $ 22,562
Investment securities 5,906 6,667
Trade accounts receivable (net of allowance of $84 and $124, respectively) 39,810 42,212
Inventories, net 32,847 27,064
Prepaid income taxes 213 2,120
Deferred tax assets 5,253 4,833
Other current assets   1,851     1,023  
Total Current Assets 118,946 106,481
 
Property, plant and equipment, net 39,288 37,068
Intangible assets, net 3,017 4,429
Deferred tax assets 8,024 9,069
Other assets   956     1,171  
TOTAL ASSETS $ 170,231   $ 158,218  
 
 

LIABILITIES

Current Liabilities
Accounts payable $ 15,709 $ 17,989
Accrued expenses 2,053 1,518
Accrued payroll and payroll related 5,347 3,198
Current portion of long-term debt 657 648
Rebates, chargebacks and returns payable   16,550     17,039  
Total Current Liabilities 40,316 40,392
 
Long-term debt, less current portion   6,125     6,513  
TOTAL LIABILITIES   46,441     46,905  
Commitment and Contingencies
 

SHAREHOLDERS' EQUITY

Common stock - authorized 50,000,000 shares, par value $0.001; issued, 29,103,931 and 28,594,437 shares, respectively; outstanding, 28,668,052 and 28,252,192 shares, respectively

29 29
Additional paid in capital 102,702 99,515
Retained earnings 22,990 13,236
Accumulated other comprehensive loss (79 ) (63 )

Treasury stock at cost - 435,879 and 342,245 shares, respectively

  (2,034 )   (1,594 )
Total Shareholders' Equity Attributable to Lannett Company, Inc. 123,608 111,123
Noncontrolling interest   182     190  
TOTAL SHAREHOLDERS' EQUITY   123,790     111,313  
 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 170,231   $ 158,218  

PondelWilkinson Inc.
Roger Pondel
(310) 279-5980


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LANNETT COMPANY, INC.
08/09 LANNETT : Announces Preliminary Fiscal 2017 Fourth Quarter and Full Year Financi..
08/08 LANNETT : Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financi..
08/01 LANNETT : To Present At The Canaccord Genuity 37th Annual Growth Conference On A..
07/19 LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements..
07/18 LANNETT : Appoints Samuel H. Israel As General Counsel
07/17 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Co. Receives Approval for ..
07/17 LANNETT : Appoints Samuel H. Israel As General Counsel
07/14 LANNETT : Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
06/28 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Receives Approval for Addi..
06/26 LANNETT : Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitar..
More news
Financials ($)
Sales 2017 654 M
EBIT 2017 242 M
Net income 2017 10,2 M
Debt 2017 798 M
Yield 2017 -
P/E ratio 2017 417,33
P/E ratio 2018 12,65
EV / Sales 2017 2,11x
EV / Sales 2018 2,09x
Capitalization 583 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,2 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Arthur P. Bedrosian Chief Executive Officer & Director
Jeffrey Farber Chairman
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Kristin A. Arnold Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
LANNETT COMPANY, INC.583
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705